Melanoma therapy: Potential goal bypasses therapeutic resistance to immune checkpoint blockers

Over the past decade, immune checkpoint blockers, or ICBs, have revolutionized therapy for varied superior cancers, together with melanoma, probably the most aggressive pores and skin most cancers that was thought of largely incurable not way back. Nevertheless, three-fourths of advanced-melanoma sufferers are immune to ICBs. Now, researchers reveal a possible goal — utilizing the clinically accepted drug ruxolitinib — to suppress ICB-resistant melanomas.